Severity of hearing loss after platinum chemotherapy in childhood cancer survivors.

Strebel, Sven; Mader, Luzius; Sláma, Tomáš; Waespe, Nicolas; Weiss, Annette; Parfitt, Ross; Am Zehnhoff-Dinnesen, Antoinette; Kompis, Martin; von der Weid, Nicolas X; Ansari, Marc; Kuehni, Claudia E (2022). Severity of hearing loss after platinum chemotherapy in childhood cancer survivors. Pediatric blood & cancer, 69(9), e29755. Wiley-Liss 10.1002/pbc.29755

[img]
Preview
Text
Strebel_PediatrBloodCancer_2022.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (742kB) | Preview

BACKGROUND

Hearing loss is a potential side effect from childhood cancer treatment. We described the severity of hearing loss assessed by audiometry in a representative national cohort of childhood cancer survivors (CCS) and identified clinical risk factors.

PROCEDURE

We included all CCS from the Swiss Childhood Cancer Registry who were diagnosed ≤18 age and treated with platinum-based chemotherapy between 1990 and 2014. We extracted audiograms, treatment-related information, and demographic data from medical records. Two reviewers independently assessed the severity of hearing loss at latest follow-up using the Münster Ototoxicity Scale. We used ordered logistic regression to identify clinical risk factors for severity of hearing loss.

RESULTS

We analyzed data from 270 CCS. Median time from cancer diagnosis to last audiogram was 5 years (interquartile range 2.5-8.1 years). We found 53 (20%) CCS with mild, 78 (29%) with moderate, and 75 (28%) with severe hearing loss. Higher severity grades were associated with (a) younger age at cancer diagnosis (odds ratio [OR] 5.4, 95% confidence interval [CI]: 2.5-12.0 for <5 years); (b) treatment in earlier years (OR 4.8, 95% CI: 2.1-11.0 for 1990-1995); (c) higher cumulative cisplatin doses (OR 13.5, 95% CI: 4.7-38.8 for >450 mg/m2 ); (d) concomitant cranial radiation therapy (CRT) (OR 4.4, 95% CI: 2.5-7.8); and (e) hematopoietic stem cell transplantation (HSCT) (OR 2.7, 95% CI: 1.0-7.2).

CONCLUSION

Three of four CCS treated with platinum-based chemotherapy experienced some degree of hearing loss. We recommend closely monitoring patient's hearing function if treated at a young age with high cumulative cisplatin doses, and concomitant CRT as part of long-term care.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ear, Nose and Throat Disorders (ENT)
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine > Paediatric Haematology/Oncology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)
Graduate School for Health Sciences (GHS)

UniBE Contributor:

Strebel, Sven, Mader, Luzius Adrian, Sláma, Tomáš, Waespe Laredo, Nicolas Thomas, Weiss, Annette Gerda, Kompis, Martin, Kühni, Claudia

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

1545-5009

Publisher:

Wiley-Liss

Funders:

[193] Swiss Cancer League = Krebsliga Schweiz ; [213] CANSEARCH Foundation ; [189] Swiss Cancer Research = Krebsforschung Schweiz ; [228] Kinderkrebshilfe Schweiz

Language:

English

Submitter:

Anette van Dorland

Date Deposited:

22 Jun 2022 14:14

Last Modified:

05 Dec 2022 16:21

Publisher DOI:

10.1002/pbc.29755

PubMed ID:

35723448

Uncontrolled Keywords:

cancer registry childhood cancer survivors cranial radiation ototoxicity platinum compounds

BORIS DOI:

10.48350/170812

URI:

https://boris.unibe.ch/id/eprint/170812

Actions (login required)

Edit item Edit item
Provide Feedback